20-22 March 2017 | Bio-Europe Spring

1-5 Apr 2017 | AACR Annual Meeting 2017

Sixth Element Capital is currently managing its first fund: the £70m CRT Pioneer Fund (CPF) to create the future of cancer therapy and diagnosis. CPF invests in oncology focused assets and companies and has a proprietary relationship with Cancer Research Technology (CRT). CPF's investors are the European Investment Fund and Syncona.